[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69626510D1 - Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten - Google Patents

Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten

Info

Publication number
DE69626510D1
DE69626510D1 DE69626510T DE69626510T DE69626510D1 DE 69626510 D1 DE69626510 D1 DE 69626510D1 DE 69626510 T DE69626510 T DE 69626510T DE 69626510 T DE69626510 T DE 69626510T DE 69626510 D1 DE69626510 D1 DE 69626510D1
Authority
DE
Germany
Prior art keywords
endothelin antagonists
inhibitor factor
leukemia inhibitor
antagonist
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69626510T
Other languages
English (en)
Other versions
DE69626510T2 (de
Inventor
Napoleone Ferrara
Kathleen King
A Luis
P Mather
F Paoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69626510D1 publication Critical patent/DE69626510D1/de
Application granted granted Critical
Publication of DE69626510T2 publication Critical patent/DE69626510T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69626510T 1995-04-24 1996-04-17 Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten Expired - Lifetime DE69626510T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42738395A 1995-04-24 1995-04-24
PCT/US1996/005498 WO1996033740A1 (en) 1995-04-24 1996-04-17 Use of leukemia inhibitory factor and endothelin antagonists

Publications (2)

Publication Number Publication Date
DE69626510D1 true DE69626510D1 (de) 2003-04-10
DE69626510T2 DE69626510T2 (de) 2003-12-11

Family

ID=23694642

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69626510T Expired - Lifetime DE69626510T2 (de) 1995-04-24 1996-04-17 Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
DE69635630T Expired - Lifetime DE69635630T2 (de) 1995-04-24 1996-04-17 Verwendung eines Leukämie-hemmenden Faktor Antagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69635630T Expired - Lifetime DE69635630T2 (de) 1995-04-24 1996-04-17 Verwendung eines Leukämie-hemmenden Faktor Antagonisten

Country Status (12)

Country Link
EP (2) EP1287832B1 (de)
JP (1) JPH11504332A (de)
AT (2) ATE313333T1 (de)
AU (1) AU702375B2 (de)
CA (1) CA2214636C (de)
DE (2) DE69626510T2 (de)
DK (2) DK0830143T3 (de)
ES (1) ES2254564T3 (de)
IL (1) IL117998A (de)
MX (1) MX9707939A (de)
WO (1) WO1996033740A1 (de)
ZA (1) ZA963274B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753197B2 (en) 1998-07-06 2002-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for in vitro fertilization
EP1549198A4 (de) * 2002-09-30 2007-03-28 Univ Duke Thymusatrophi
JP2011231014A (ja) * 2008-08-27 2011-11-17 Keiichi Fukuda 心不全の治療剤
EP2371860A1 (de) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Den humanen leukaemieinhibierenden Faktor (LIF) erkennender Antikörper und Verwendung von LIF-Antikörpern bei der Behandlung von Krankheiten im Zusammenhang mit ungewollter Zellproliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
CN118652335A (zh) 2016-12-19 2024-09-17 免疫医疗有限公司 抗lif抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists

Also Published As

Publication number Publication date
DK0830143T3 (da) 2003-06-16
EP1287832A2 (de) 2003-03-05
ZA963274B (en) 1997-10-24
EP0830143A1 (de) 1998-03-25
AU5665896A (en) 1996-11-18
CA2214636C (en) 2009-12-22
IL117998A0 (en) 1996-08-04
JPH11504332A (ja) 1999-04-20
ATE313333T1 (de) 2006-01-15
ES2254564T3 (es) 2006-06-16
DE69626510T2 (de) 2003-12-11
DE69635630T2 (de) 2006-08-10
DK1287832T3 (da) 2006-05-01
CA2214636A1 (en) 1996-10-31
EP0830143B1 (de) 2003-03-05
MX9707939A (es) 1997-12-31
ATE233570T1 (de) 2003-03-15
IL117998A (en) 2001-04-30
AU702375B2 (en) 1999-02-18
EP1287832A3 (de) 2003-04-16
WO1996033740A1 (en) 1996-10-31
DE69635630D1 (de) 2006-01-26
EP1287832B1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
DE69230140D1 (de) Antivirale nucleosidkombination
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
AU9058591A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic nephropathy
DK0804229T3 (da) Anvendelse af amlodipin, et salt deraf eller felodipin i kombination med en ACE-inhibitor til fremstilling af et medikament til behandling af non-ikæmisk kongestiv hjertefejl
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
DE69626510D1 (de) Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
FI954614A0 (fi) Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
NO990450L (no) Behandling av sinnslidelser
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
EP0116628A4 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
ES8700940A1 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus
BR0009642A (pt) Terapia de leucemia mielocìtica crÈnica
DE59409746D1 (de) Verwendung von lithiumverbindungen zur behandlung von herzinsuffizienz
KR950008161U (ko) 개인용 찜질사우나
DK332786D0 (da) Anvendelse af 1,4-dihydropyridinderivater og kombinationer deraf med calcitoniner
FI871737A0 (fi) Kraftanlaeggning med foerbraenning i en fluidiserad baedd.
IT207511Z2 (it) Struttura legnosa multistrato, opportunamente curvata e lavorata, per la realizzazione di letti di tipo anatomico.
ITRM920516A1 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.
MX9701294A (es) Un medicamento que contiene un derivado de carnitina para el tratamiento de la arterioesclerosis cronica obliteradora.
ITFI920049V0 (it) Metodo personal plan - materiale per organizzazione e gestione del tempo lavoro

Legal Events

Date Code Title Description
8364 No opposition during term of opposition